Evolent Health Q4 revenue slightly misses analyst expectations

Evolent Health

24/02/2026 21:42

Overview

Healthcare solutions provider's Q4 revenue slightly missed analyst expectations

Company forecasts 30% revenue growth for 2026

Outlook

Company expects 2026 revenue between $2.4 bln and $2.6 bln

Evolent projects 2026 adjusted EBITDA between $110 mln and $140 mln

Company plans $25 mln to $35 mln investment in software development for 2026

Result Drivers

PERFORMANCE SUITE REVENUE - Evolent added $900 mln in new Performance Suite revenue for 2026, impacting adjusted EBITDA in the first half

Company press release: ID:nPnb4rTgJa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Miss*
$468.72 mln
$468.81 mln (15 Analysts)
Q4 Net Income
-$429.13 mln
Q4 Adjusted EBITDA
$37.79 mln
Q4 Adjusted EBITDA Margin
8.10%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Evolent Health Inc is $8.50, about 206.9% above its February 23 closing price of $2.77

The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 27 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)